These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 10216419)
1. Comparing therapeutic benefit and risk. Meyboom RH; Egberts AC Therapie; 1999; 54(1):29-34. PubMed ID: 10216419 [TBL] [Abstract][Full Text] [Related]
2. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
3. [Procedures and methods of benefit assessments for medicines in Germany]. Bekkering GE; Kleijnen J Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813 [TBL] [Abstract][Full Text] [Related]
4. How to anticipate the assessment of the public health benefit of new medicines? Massol J; Puech A; Boissel JP; Therapie; 2007; 62(5):427-35. PubMed ID: 18206104 [TBL] [Abstract][Full Text] [Related]
5. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis. Mussen F; Salek S; Walker S Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573 [TBL] [Abstract][Full Text] [Related]
6. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
7. The role of scientific evidence of risks and benefits in determining risk management policies for medications. Andrews E; Dombeck M Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082 [TBL] [Abstract][Full Text] [Related]
8. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1. Lunsford LD; Flickinger JC; Larson D Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030 [TBL] [Abstract][Full Text] [Related]
10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
12. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Eichler HG; Pignatti F; Flamion B; Leufkens H; Breckenridge A Nat Rev Drug Discov; 2008 Oct; 7(10):818-26. PubMed ID: 18787530 [TBL] [Abstract][Full Text] [Related]
13. On the Way to New Horizons: Telemedicine in Oncology. Schlag PM Oncologist; 1997; 2(2):III-IV. PubMed ID: 10388041 [TBL] [Abstract][Full Text] [Related]
14. [New evidence-based criteria for evaluating the appropriateness of drug regimen in seniors. Criteria STOPP (screening tool of older person's prescriptions) and START (screening tool to alert doctors to right treatment)]. Topinková E; Mádlová P; Fialová D; Klán J Vnitr Lek; 2008 Dec; 54(12):1161-9. PubMed ID: 19140525 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of treatment risks: taking clinical data, pharmacology and patient characteristics into account. Prescrire Int; 2010 Feb; 19(105):44-5. PubMed ID: 20455347 [TBL] [Abstract][Full Text] [Related]
16. A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis. Tervonen T; van Valkenhoef G; Buskens E; Hillege HL; Postmus D Stat Med; 2011 May; 30(12):1419-28. PubMed ID: 21268053 [TBL] [Abstract][Full Text] [Related]
17. Priorities in the benefit-risk assessment of new drugs. Venning GR Adverse Drug React Acute Poisoning Rev; 1984; 3(2):113-21. PubMed ID: 6543414 [TBL] [Abstract][Full Text] [Related]
18. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Griebsch I; Coast J; Brown J Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026 [TBL] [Abstract][Full Text] [Related]
19. Interpretation of drug risk and benefit: individual and population perspectives. Bjornson DC Ann Pharmacother; 2004 Apr; 38(4):694-9. PubMed ID: 14990777 [TBL] [Abstract][Full Text] [Related]
20. [Conclusions. The precautionary principle: its advantages and risks]. Tubiana M Bull Acad Natl Med; 2000; 184(5):969-93. PubMed ID: 11077719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]